Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:10:31 16/07/2024 pm IST			5-day change	1st Jan Change
1,185 ^INR	-0.27%		+1.66%	+71.91%

09:59am	Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India	MT
09:28am	Zydus Lifesciences Limited Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceutical Company for `Vault®' in India	CI

Sun Pharma, Cadila, Aurobindo and Torrent Eyes Stake In Manufacturing Assets In The US

January 19, 2018 at 10:30 am IST

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), Aurobindo Pharma Limited (BSE:524804), Cadila Healthcare Limited (BSE:532321) and Torrent Pharmaceuticals Limited (BSE:500420) are looking to acquire manufacturing assets in the US.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
TORRENT PHARMACEUTICALS LIMITED	2,973 INR	+0.75%	+1.27%	1.2TCr
SUN PHARMACEUTICAL INDUSTRIES LTD.	1,579 INR	-0.44%	-0.38%	4.53TCr
AUROBINDO PHARMA	1,371 INR	-0.28%	+2.90%	961.39Cr

Latest news about Zydus Lifesciences Limited

Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India	01:29pm	MT
Zydus Lifesciences Limited Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceutical Company for `Vault®' in India	12:58pm	CI
Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Multiple Sclerosis Drug	11/07	MT
Zydus Lifesciences Gets US FDA's Final Nod for Sacubitril, Valsartan Tablets	11/07	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg	10/07	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Sacubitril and Valsartan Tablets	10/07	CI
Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Hypertension Drug; Shares Up 4%	04/07	MT
Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg	04/07	CI
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India	28/06	MT
Zydus and Dr. Reddy's Announces Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar, a Critical Treatment for Breast Cancer Patients in India	28/06	CI
Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Hypertension Drug	14/06	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets	14/06	CI
India's pharma export sales to grow faster this year, trade body says	30/05	RE
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	27/05	RE
Zydus Completes Patient Enrolment for Phase II Clinical Trial of Usnoflast in ALS Patients	24/05	MT
Zydus Lifesciences Limited Announces Completion of Enrolment for Phase II Clinical Trial of Usnoflast, Novel Oral Nlrp3 Inflammasome Inhibitor in Patients with Amyotrophic Lateral Sclerosis	24/05	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Theophylline Extended-Release Tablets, 300 Mg and 450 Mg	22/05	CI
Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	21/05	MT
Zydus Lifesciences Records Sharp Rise in Fiscal Q4 Consolidated Profit	21/05	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,070 From INR750, Keeps at Hold	20/05	MT
Transcript : Zydus Lifesciences Limited, Q4 2024 Earnings Call, May 17, 2024	17/05
Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024	17/05	CI
Zydus Lifesciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	17/05	CI
Zydus Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	17/05	CI
Zydus Lifesciences Gets US FDA Nod to Market Dexamethasone Tablets	13/05	MT

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,185 INR

Average target price

1,029 INR

Spread / Average Target

-13.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+71.91%	1.43TCr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	4.53TCr
OTSUKA HOLDINGS CO., LTD.	+38.38%	2.43TCr
SANDOZ GROUP AG	+26.90%	1.65TCr
CIPLA LIMITED	+21.19%	1.46TCr
THE MEDICINES COMPANY	-0.05%	678.76Cr
ONO PHARMACEUTICAL CO., LTD.	-11.63%	656.86Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+15.08%	576.04Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
KRKA, D. D.	+35.91%	501.47Cr

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Sun Pharma, Cadila, Aurobindo and Torrent Eyes Stake In Manufacturing Assets In The US

Stocks mentioned in the article

EPS Revisions